Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Clinical Cancer Research

• Publication date

  1998-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 9533550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis

  2005cited by this paper
• Intraperitoneal immunotherapy of peritoneal carcinomatosis.

  1998cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• Mitogen-Induced Lymphocyte Proliferation and Systemic Immune Activation in Cancer Patients

  1996cited by this paper
• Dendritic cells from different tissues induce production of different T cell cytokine profiles

  1996cited by this paper
• Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

  1996cited by this paper
• Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.

  1996cited by this paper
• Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.

  1996cited by this paper
• Normal Human Immune Peritoneal Cells: Subpopulations and Functional Characteristics

  1996cited by this paper
• HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.

  1996cited by this paper
• Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

  1996cited by this paper
• Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.

  1996cited by this paper
• Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells

  1996cited by this paper
• Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

  1996cited by this paper
• IL‐12‐Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivo a

  1996cited by this paper
• Interferon-gamma and tumor necrosis factor-alpha treatment of ex vivo human carcinoma cells potentiates their interaction with allogeneic lymphocytes.

  1996cited by this paper
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

  1996cited by this paper
• Dendritic cells: from ontogenetic orphans to myelomonocytic descendants.

  1996cited by this paper
• Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

  1996cited by this paper
• Collagenase and Dispase enzymes disrupt lymphocyte surface molecules.

  1996cited by this paper
• Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression.

  1995cited by this paper
• Interleukin‐10 differentially regulates B7‐1 (CD80) and B7‐2 (CD86) expression on human peripheral blood dendritic cells

  1995cited by this paper
• CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

  1995cited by this paper
• The B7 and CD28 receptor families.

  1994cited by this paper
• Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.

  1994cited by this paper
• Expression of the co‐stimulatory molecule B7 on melanoma cells

  1994cited by this paper
• Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature.

  1994cited by this paper
• CD4+ blood dendritic cells are potent producers of IFN-alpha in response to in vitro HIV-1 infection.

  1994cited by this paper
• Functional expression of B7/BB1 on activated T lymphocytes

  1993cited by this paper
• Comparative accessory cell function of human peripheral blood dendritic cells and monocytes.

  1993cited by this paper
• Antigen‐presenting capacity of macrophages and dendritic cells in the peritoneal cavity of patients treated with peritoneal dialysis

  1993cited by this paper
• Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium

  1993cited by this paper
• Neopterin and prognosis in patients with adenocarcinoma of the colon.

  1993cited by this paper
• The role of the CD28 receptor during T cell responses to antigen.

  1993cited by this paper
• HLA-DR antigen- and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma— Their distribution in relation to prognosis

  1992cited by this paper
• The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro.

  1992cited by this paper
• The dendritic cell system and its role in immunogenicity.

  1991cited by this paper
• Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer.

  1990cited by this paper
• Interactions Between Epithelial Cells and T Lymphocytes: Role of Adhesion Molecules

  1990cited by this paper
• Accessory Cell Signals Involved in T‐Cell Activation

  1990cited by this paper
• Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.

  1990cited by this paper
• The T cell receptor.

  1987cited by this paper
• Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix.

  1986cited by this paper
• The B 7 and CD 28 receptor families

  year unknowncited by this paper

• Circulating concentrations of citrulline, neopterin, kynurenine, and tryptophan during chemoradiation in patients with cervical carcinoma

  2021cites this paper
• Precision medicine in medical oncology: hope, disappointment and reality

  2020cites this paper
• Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report

  2020cites this paper
• Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study

  2019cites this paper
• Comparison of performance of composite biomarkers of inflammatory response in determining the prognosis of breast cancer patients

  2017cites this paper
• Immunological Analysis and Generation of Dendritic Cells From Lavage Fluid Obtained by Cell‐Free and Concentrated Ascites Reinfusion Therapy

  2017cites this paper
• Antibody-mediated depletion of immunosuppressive factors from ovarian carcinoma-associated ascites for investigation of paracrine versus autocrine effects

  2017cites this paper
• Concentrations of neopterin, kynurenine and tryptophan in wound secretions of patients with breast cancer and malignant melanoma: a pilot study

  2017cites this paper
• Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers)

  2017cites this paper
• Protein Concentration of Refractory Ascites in Cancer Patients is Reflected by the Presence and Severity of Peritoneal and Liver Metastasis

  2017cites this paper
• Association of peripheral blood cell count-derived ratios, biomarkers of inflammatory response and tumor growth with outcome in previously treated metastatic colorectal carcinoma patients receiving cetuximab

  2017cites this paper
• Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study

  2017cites this paper
• Salivary neopterin concentrations in patients with cancer of the oral cavity

  2016cites this paper
• Prolonged response to pemetrexed-based chemotherapy in a patient with peritoneal mesothelioma: a case report and review of the literature

  2016cites this paper
• Fast and sensitive HPLC method for the determination of neopterin, kynurenine and tryptophan in amniotic fluid, malignant effusions and wound exudates.

  2015cites this paper
• Tumor-Induced Immune Suppression

  2014influential citation
• Immunobiology of Dendritic Cells in Cancer

  2014cites this paper
• Urinary neopterin concentrations during combination therapy with cetuximab in previously treated patients with metastatic colorectal carcinoma.

  2014cites this paper
• Microglial Regulation by Astrocytes: Effect on CD40 Surface Expression and Its Consequences for Dendritic Cell Maturation

  2013cites this paper
• Prognostic Significance of Serum Neopterin in Patients with Esophageal Carcinoma

  2012cites this paper
• Ovarian Cancer Immunology and Immunotherapy

  2011cites this paper
• Prognostic significance of increased urinary neopterin concentrations in patients with breast carcinoma.

  2011cites this paper
• Correlation of Peripheral Blood CD14+CD16+ Monocytes, Urinary Neopterin and the Risk Factors of Atherosclerosis in Patients with Breast Carcinoma

  2011cites this paper
• Peritoneal Immune System in Patients with Advance Epithelial Ovarian Cancer

  2011influential citation
• The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

  2010cites this paper
• Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer

  2010cites this paper
• Neopterin, a prognostic marker in human malignancies.

  2010cites this paper
• Immunopathogenesis of ovarian cancer.

  2009cites this paper
• Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses

  2009cites this paper
• Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials

  2009cites this paper
• Regulatory T cells: What role do they play in antitumor immunity in patients with head and neck cancer?

  2008cites this paper
• The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment.

  2008cites this paper
• The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer microenvironment

  2007influential citation
• Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck

  2006cites this paper
• Journal of Translational Medicine Cytokines, Gm-csf and Ifnγ Administered by Priming and Post-chemotherapy Cycling in Recurrent Ovarian Cancer Patients Receiving Carboplatin

  2006cites this paper
• Ovarian Carcinoma Cells Effectively Inhibit Differentiation and Maturation of Dendritic Cells Derived from Hematopoietic Progenitor Cells In Vitro

  2005cites this paper
• Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes

  2005cites this paper
• Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC)

  2004cites this paper
• Restoration of tumor specific human leukocyte antigens class I‐restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer

  2004cites this paper
• Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer

  2004cites this paper
• Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies

  2004cites this paper
• Vaccine Therapy for Breast and Ovarian Cancers

  2004cites this paper
• Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma

  2003cites this paper
• Increased serum transforming growth factor‐β1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration

  2003cites this paper
• Evaluation of Myeloid and Lymphoid Dendritic Cells in Peritoneal Fluid in Women with Non‐malignant Ovarian Tumors

  2003cites this paper
• Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas.

  2003cites this paper
• Immune responses to human tumors: development of tumor vaccines.

  2003cites this paper
• Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.

  2003cites this paper
• Intraperitoneal Fluid Neopterin, Nitrate, and Tryptophan After Regional Administration of Interleukin-12

  2003cites this paper
• The immunotherapy of patients with ovarian cancer.

  2002cites this paper
• Identification of Biologically Active Chemokine Isoforms from Ascitic Fluid and Elevated Levels of CCL18/Pulmonary and Activation-regulated Chemokine in Ovarian Carcinoma*

  2002cites this paper
• Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck.

  2002cites this paper
• Increased levels of interleukin‐10 and transforming growth factor‐β in the plasma and ascitic fluid of patients with advanced ovarian cancer

  2001cites this paper
• The identification of dendritic cells in cancer

  2001cites this paper
• Immunology of the peritoneal cavity: Relevance for host-tumor relation

  2001cites this paper
• Current strategies in gene therapy for ovarian cancer

  2001cites this paper
• Maturation of dendritic cells from ovarian cancer patients

  2001cites this paper
• Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.

  2001cites this paper
• Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer.

  2001cites this paper
• Clinical and Biological Effects of Intraperitoneal Injections of Recombinant Interferon-g and Recombinant Interleukin 2 with or without Tumor-infiltrating Lymphocytes in Patients with Ovarian or Peritoneal Carcinoma 1

  2000cites this paper
• Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.

  2000cites this paper
• Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA‐4 on malignant ascites CD3+ tumour‐infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis

  2000cites this paper
• Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma

  2000cites this paper
• The role of cytokines in both the normal and malignant ovary.

  1999cites this paper
• Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.

  1999cites this paper
• Expression and Proliferation of Autologous T Carcinoma That Inhibits Cytokine Protein Malignant Ascites of Patients with Ovarian HLA-DR-Negative Monocyte Subset in the Identification of an IL-10-Producing

  1999cites this paper
• Vaccines for Ovarian Carcinoma.

  1999cites this paper
• Intraperitoneal immunotherapy of peritoneal carcinomatosis.

  1998cites this paper
• Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour‐infiltrating lymphocyte (TIL)‐derived T cell lines and established tumour cell lines

  1998cites this paper